Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Bio-Gene Technology Ltd. ( (AU:BGT) ).
Bio-Gene Technology Limited released its 2025 Annual Report, highlighting a year marked by a 100% decrease in revenue from ordinary activities and a 7.3% increase in losses after tax. Despite these financial challenges, the company continues to focus on its mission to provide innovative bio-insecticide solutions. The report, approved by the Board of Directors, underscores the company’s commitment to addressing insecticide resistance and toxicity issues, although no dividends were declared for the year.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian company specializing in the development of novel bio-insecticides. These products aim to tackle global challenges related to insecticide resistance and toxicity by utilizing naturally occurring compounds. The company’s offerings, including Flavocide and Qcide, are designed for applications in public health, crop protection, grain storage, and consumer use, providing environmentally friendly pest management solutions.
Average Trading Volume: 242,325
Technical Sentiment Signal: Sell
Current Market Cap: A$6.41M
For detailed information about BGT stock, go to TipRanks’ Stock Analysis page.